Neurosteroid and neurotransmitter alterations in Parkinson's disease

Frontiers in Neuroendocrinology

Volumn 34, Issue 2, 2013, Pages 132-142

  Di Michele, Flavia ^a   Luchetti, Sabina ^b   Bernardi, Giorgio ^a,c   Romeo, Elena ^d   Longone, Patrizia ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Dopamine; GABAA; Neurosteroids; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; DOPAMINE; MESSENGER RNA; NEUROSTEROID; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ELTANOLONE; NEUROPROTECTIVE AGENT;

BASAL GANGLION; CELL SURVIVAL; DENERVATION; DOPAMINERGIC NERVE CELL; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE EXPRESSION; HORMONE ACTION; HUMAN; MOLECULAR INTERACTION; NERVE CELL NETWORK; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; ANIMAL; BRAIN; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PHYSIOLOGY; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; GABA-A RECEPTOR AGONISTS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PREGNANOLONE; RECEPTORS, GABA-A; SUBSTANTIA NIGRA;

EID: 84877640168     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2013.03.001     Document Type: Review

References (213)

1. Adeosun S.O., Hou X., Jiao Y., Zheng B., Henry S., Hill R., He Z., Pani A., Kyle P., Ou X., Mosley T., Farley J.M., Stockmeier C., Paul I., Bigler S., Brinton R.D., Smeyne R., Wang J.M. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One 2012, 7(11):e50040.
2. Akk G., Shu H.J., Wang C., Steinbach J.H., Zorumski C.F., Covey D.F., Mennerick S. Neurosteroid access to the GABAA receptor. J. Neurosci. 2005, 25:11605-11613.
3. Al Sweidi S., Sánchez M.G., Bourque M., Morissette M., Dluzen D., Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J. Neuroendocrinol. 2012, 24:48-61.
4. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 1990, 85:119-146.
5. Aller M.I., Janusonis S., Fite K.V., Fernández-López A. Distribution of the GABAA receptor complex beta 2/3 subunits in the brain of the frog Rana pipiens. Neurosci. Lett. 1997, 225:65-68.
6. Ampe B., Massie A., D'Haens J., Ebinger G., Michotte Y., Sarre S. NMDA-mediated release of glutamate and GABA in the subthalamic nucleus is mediated by dopamine: an in vivo microdialysis study in rats. J. Neurochem. 2007, 103:1063-1074.
7. Bäckberg M., Ultenius C., Fritschy J.M., Meister B. Cellular localization of GABA receptor alpha subunit immunoreactivity in the rat hypothalamus: relationship with neurones containing orexigenic or anorexigenic peptides. J. Neuroendocrinol. 2004, 16:589-604.
8. Baulieu E.E., Schumacher M., Koenig H., Jung-Testas I., Akwa Y. Progesterone as a neurosteroid: actions within the nervous system. Cell. Mol. Neurobiol. 1996, 16:143-154.
9. Baulieu E.E., Robel P., Schumacher M. Neurosteroids: beginning of the story. Int. Rev. Neurobiol. 2001, 46:1-32.
10. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci. 2005, 6:565-575.
11. Benavides J., Peny B., Durand A., Arbilla S., Scatton B. Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system. J. Pharmacol. Exp. Ther. 1992, 263:884-896.
12. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72:507-520.
13. Bernal-Pacheco O., Limotai N., Go C.L., Fernandez H.H. Non motor manifestations in Parkinson disease. Neurologist 2012, 18:1-16.
14. Bianchi M.T., Macdonald R.L. Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns. J. Neurosci. 2003, 23:10934-10943.
15. Biggio F., Gorini G., Caria S., Murru L., Mostallino M.C., Sanna E., Follesa P. Plastic neuronal changes in GABA(A) receptor gene expression induced by progesterone metabolites: in vitro molecular and functional studies. Pharmacol. Biochem. Behav. 2006, 84:545-554.
16. Biggio G., Concas A., Follesa P., Sanna E., Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol. Ther. 2007, 116:140-171.
17. Bixo M., Andersson A., Winblad B., Purdy R.H., Bäckström T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997, 764:173-178.
18. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 2000, 62:63-88.
19. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30:142-157.
20. Brown L.L., Markman M.H., Wolfson L.I., Dvorkin B., Warner C., Katzman R. A direct role of dopamine in the rat subthalamic nucleus and an adjacent intrapeduncular area. Science 1979, 206:1416-1418.
21. Brunton P.J., Russell J.A. Neuroendocrine control of maternal stress responses and fetal programming by stress in pregnancy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 35:1178-1191.
22. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993, 116:433-452.
23. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30:211-219.
24. Callier S., Morissette M., Grandbois M., Pélaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
25. Calon F., Goulet M., Blanchet P.J., Martel J.C., Piercey M.F., Bédard P.J., Di Paolo T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 1995, 680:43-52.
26. Cantuti-Castelvetri I., Keller-McGandy C., Bouzou B., Asteris G., Clark T.W., Frosch M.P., Standaert D.G. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 2007, 26:606-614.
27. Carta A.R., Fenu S., Pala P., Tronci E., Morelli M. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 2003, 18:2563-2572.
28. Celada P., Paladini C.A., Tepper J.M. GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata. Neuroscience 1999, 89:813-825.
29. Cepeda C., Levine M.S. Dopamine and N-methyl-d-aspartate receptor interactionsin the neostriatum. Dev. Neurosci. 1998, 20:1-18.
30. Chadha A., Dawson L.G., Jenner P.G., Duty S. Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience 2000, 95:119-126.
31. Chao O.Y., Huston J.P., von Bothmer A., Pum M.E. Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exasperates parkinsonian symptoms. Neuroscience 2011, 196:228-236.
32. Charalampopoulos I., Alexaki V.I., Tsatsanis C., Minas V., Dermitzaki E., Lasaridis I., Vardouli L., Stournaras C., Margioris A.N., Castanas E., Gravanis A. Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann. N. Y. Acad. Sci. 2006, 1088:139-152.
33. Charara A., Smith Y., Parent A. Glutamatergic inputs from the pedunculopontine nucleus to midbrain dopaminergic neurons in primates: phaseolus vulgaris-leucoagglutinin anterograde labeling combined with postembedding glutamate and GABA immunohistochemistry. J. Comp. Neurol. 1996, 364:254-266.
34. Ciriza I., Azcoitia I., Garcia-Segura L.M. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J. Neuroendocrinol. 2004, 16:58-63.
35. Cobb W.S., Abercrombie E.D. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent. Neuroscience 2003, 119:777-786.
36. Concas A., Mostallino M.C., Porcu P., Follesa P., Barbaccia M.L., Trabucchi M., Purdy R.H., Grisenti P., Biggio G. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc. Natl. Acad. Sci. USA 1998, 95:13284-13289.
37. Cooper E.J., Johnston G.A., Edwards F.A. Effects of a naturally occurring neurosteroid on GABAA IPSCs during development in rat hippocampal or cerebellar slices. J. Physiol. 1999, 521:437-449.
38. Covey D.F., Evers A.S., Mennerick S., Zorumski C.F., Purdy R.H. Recent developments in structure-activity relationships for steroid modulators of GABA(A) receptors. Brain Res. Brain Res. Rev. 2001, 37:91-97.
39. Członkowska A.I., Krzaścik P., Sienkiewicz-Jarosz H., Siemiatkowski M., Szyndler J., Maciejak P., Bidziński A., Płaźnik A. Tolerance to the anticonvulsant activity of midazolam and allopregnanolone in a model of picrotoxin seizures. Eur. J. Pharmacol. 2001, 425:121-127.
40. Dazzi L., Serra M., Seu E., Cherchi G., Pisu M.G., Purdy R.H., Biggio G. Progesterone enhances ethanol-induced modulation of mesocortical dopamine neurons: antagonism by finasteride. J. Neurochem. 2002, 83:1103-1109.
41. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
42. de Souza Silva M.A., Topic B., Huston J.P., Mattern C. Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats. Neuroscience 2008, 157:196-203.
43. DeLong M.R., Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 2007, 64:20-24.
44. Deniau J.M., Kitai S.T., Donoghue J.P., Grofova I. Neuronal interactions in the substantia nigra pars reticulata through axon collaterals of the projection neurons. An electrophysiological and morphological study. Exp. Brain Res. 1982, 47:105-113.
45. Deniau J.M., Mailly P., Maurice N., Charpier S. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog. Brain Res. 2007, 160:151-172.
46. Desce J.M., Godeheu G., Galli T., Artaud F., Chéramy A., Glowinski J. l-glutamate-evoked release of dopamine from synaptosomes of the rat striatum: involvement of AMPA and N-methyl-d-aspartate receptors. Neuroscience 1992, 47:333-339.
47. di Michele F., Lekieffre D., Pasini A., Bernardi G., Benavides J., Romeo E. Increased neurosteroids synthesis after brain and spinal cord injury in rats. Neurosci. Lett. 2000, 284:65-68.
48. di Michele F., Longone P., Romeo E., Lucchetti S., Brusa L., Pierantozzi M., Bassi A., Bernardi G., Stanzione P. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol. Sci. 2003, 24:172-173.
49. Di Paolo T., Lévesque D., Daigle M. A physiological dose of progesterone affects rat striatum biogenic amine metabolism. Eur. J. Pharmacol. 1986, 125:11-16.
50. Djebaili M., Guo Q., Pettus E.H., Hoffman S.W., Stein D.G. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J. Neurotrauma 2005, 22:106-118.
51. Dluzen D.E., Anderson L.I. Estrogen differentially modulates nicotine-evoked dopamine release from the striatum of male and female rats. Neurosci. Lett. 1997, 230:140-142.
52. Dluzen D.E., McDermott J.L., Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 1996, 66:658-666.
53. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front. Neuroendocrinol. 2009, 30:259-301.
54. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Vaudry D., Luu-The V., Tonon M.C., Tsutsui K., Pelletier G., Vaudry H. Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides. Front. Neuroendocrinol. 2012, 3:4.
55. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., Watanabe H., Costa E., Guidotti A. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA 2001, 98:2849-2854.
56. Eisenman L.N., He Y., Fields C., Zorumski C.F., Mennerick S. Activation-dependent properties of pregnenolone sulfate inhibition of GABAA receptor-mediated current. J. Physiol. 2003, 550:679-691.
57. Emir U.E., Tuite P.J., Öz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One 2012, 7:e30918.
58. Engel S.R., Grant K.A. Neurosteroids and behavior. Int. Rev. Neurobiol. 2001, 46:321-348.
59. Erol C., Ozben S., Ozer F., Cetin S., Tiras R. Bilateral ballism induced by gabapentin in idiopatic Parkinson's disease. Clin. Neurol. Neurosurg. 2009, 111:397-401.
60. Eser D., Schüle C., Baghai T.C., Romeo E., Uzunov D.P., Rupprecht R. Neuroactive steroids and affective disorders. Pharmacol. Biochem. Behav. 2006, 84:656-666.
61. Exposito I., Sanz B., Porras A., Mora F. Effects of apomorphine and l-methionine sulphoximine on the release of excitatory amino acid neurotransmitters and glutamine in the striatum of the conscious rat. Eur. J. Neurosci. 1994, 6:287-291.
62. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
63. Ferraz A.C., Matheussi F., Szawka R.E., Rizelio V., Delattre A.M., Rigon P., Hermel Edo E., Xavier L.L., Achaval M., Anselmo-Franci J.A. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem. Res. 2008, 33:1238-1246.
64. Filion M., Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 1991, 547:142-151.
65. Forster G.L., Blaha C.D. Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur. J. Neurosci. 2003, 17:751-762.
66. Friedman L.K., Gibbs T.T., Farb D.H. Gamma-aminobutyric acidA receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. Brain Res. 1996, 707:100-109.
67. Galeffi F., Bianchi L., Bolam J.P., Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 2003, 18:856-868.
68. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003, 17:1957-1959.
69. George O., Vallée M., Le Moal M., Mayo W. Neurosteroids and cholinergic systems: implications for sleep and cognitive processes and potential role of age-related changes. Psychopharmacology 2006, 186:402-413.
70. Ghoumari A.M., Ibanez C., El-Etr M., Leclerc P., Eychenne B., O'Malley B.W., Baulieu E.E., Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem. 2003, 86:848-859.
71. Gibbs R.B. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res. 1998, 787:259-268.
72. Gillies G.E., McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 2010, 62:155-198.
73. González S.L., Labombarda F., González Deniselle M.C., Guennoun R., Schumacher M., De Nicola A.F. Progesterone up-regulates neuronal brain-derived neurotrophic factor expression in the injured spinal cord. Neuroscience 2004, 125:605-614.
74. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA 1999, 96:13512-13517.
75. Griffiths P.D., Sambrook M.A., Perry R., Crossman A.R. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J. Neurol. Sci. 1990, 100:131-136.
76. Grillner S., Hellgren J., Ménard A., Saitoh K., Wikström M.A. Mechanisms for selection of basic motor programs: roles for the striatum and pallidum. Trends Neurosci. 2005, 28:364-370.
77. Grossman K.J., Goss C.W., Stein D.G. Effects of progesterone on the inflammatory response to brain injury in the rat. Brain Res. 2004, 1008:29-39.
78. Gulinello M., Gong Q.H., Li X., Smith S.S. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res. 2001, 910:55-66.
79. Guridi J., Herrero M.T., Luquin M.R., Guillén J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., Obeso J.A. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996, 119:1717-1727.
80. Hagell P., Odin P., Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov. Disord. 1998, 13:34-38.
81. Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol. Ther. 2007, 116:20-34.
82. Hikosaka O. GABAergic output of the basal ganglia. Prog. Brain Res. 2007, 160:209-226.
83. Hnasko T.S., Hjelmstad G.O., Fields H.L., Edwards R.H. Ventral tegmental area glutamate neurons: electrophysiological properties and projections. J. Neurosci. 2012, 32:15076-15085.
84. Hollis D.M., Boyd S.K. Distribution of GABA-like immunoreactive cell bodies in the brains of two amphibians, Rana catesbeiana and Xenopus laevis. Brain Behav. Evol. 2005, 65:127-142.
85. Hosie A.M., Wilkins M.E., da Silva H.M., Smart T.G. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006, 444(7118):486-489.
86. Iribe Y., Moore K., Pang K.C., Tepper J.M. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol. 1999, 82:925-933.
87. Johnson S.W., North R.A. Two types of neurones in the rat ventral tegmental area and their synaptic inputs. J. Physiol. 1992, 450:455-468.
88. Kalivas P.W., Duffy P. Dopamine regulation of extracellular glutamate in the nucleus accumbens. Brain Res. 1997, 761:173-177.
89. Katz J., Nielsen K.M., Soghomonian J.J. Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata. Neuroscience 2005, 132:833-842.
90. Kaur P., Jodhka P.K., Underwood W.A., Bowles C.A., de Fiebre N.C., de Fiebre C.M., Singh M. Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants. J. Neurosci. Res. 2007, 85:2441-2449.
91. Kelley M.H., Taguchi N., Ardeshiri A., Kuroiwa M., Hurn P.D., Traystman R.J., Herson P.S. Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and Allopregnanolone neuroprotection is associated with GABAA receptor stabilization. J. Neurochem. 2008, 107:668-678.
92. Khisti R.T., Deshpande L.S., Chopde C.T. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents. Psychopharmacology 2002, 161:120-128.
93. Kish S.J., Rajput A., Gilbert J., Rozdilsky B., Chang L.J., Shannak K., Hornykiewicz O. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann. Neurol. 1986, 20:26-31.
94. Kita H., Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 1987, 260:435-452.
95. Koenig H.L., Schumacher M., Ferzaz B., Thi A.N., Ressouches A., Guennoun R., Jung-Testas I., Robel P., Akwa Y., Baulieu E.E. Progesterone synthesis and myelin formation by Schwann cells. Science 1995, 268:1500-1503.
96. Laconi M.R., Cabrera R.J. Effect of centrally injected allopregnanolone on sexual receptivity, luteinizing hormone release, hypothalamic dopamine turnover, and release in female rats. Endocrine 2002, 17:77-83.
97. Lambert J.J., Belelli D., Hill-Venning C., Callachan H., Peters J.A. Neurosteroid modulation of native and recombinant GABAA receptors. Cell. Mol. Neurobiol. 1996, 16:155-174.
98. Lambert J.J., Harney S.C., Belelli D., Peters J.A. Neurosteroid modulation of recombinant and synaptic GABAA receptors. Int. Rev. Neurobiol. 2001, 461:77-205.
99. Lancel M., Faulhaber J., Schiffelholz T., Romeo E., di Michele F., Holsboer F., Rupprecht R. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J. Pharmacol. Exp. Ther. 1997, 282:1213-1218.
100. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1130-1143.
101. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
102. Lee C.R., Tepper J.M. Basal ganglia control of substantia nigra dopaminergic neurons. J. Neural Transm. Suppl. 2009, 73:71-90.
103. Levy R., Ashby P., Hutchison W.D., Lang A.E., Lozano A.M., Dostrovsky J.O. Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain 2002, 125:1196-1209.
104. Liu A., Margaill I., Zhang S., Labombarda F., Coqueran B., Delespierre B., Liere P., Marchand-Leroux C., O'Malley B.W., Lydon J.P., De Nicola A.F., Sitruk-Ware R., Mattern C., Plotkine M., Schumacher M., Guennoun R. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology 2012, 153:3747-3757.
105. Lockhart E.M., Warner D.S., Pearlstein R.D., Penning D.H., Mehrabani S., Boustany R.M. Allopregnanolone attenuates N-methyl-d-aspartate-induced excitotoxicity and apoptosis in the human NT2 cell line in culture. Neurosci. Lett. 2002, 328:33-36.
106. Luchetti S., di Michele F., Romeo E., Brusa L., Bernardi G., Cummings J.B., Longone P. Comparative non-radioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans. J. Neurosci. Methods 2006, 153:290-298.
107. Luchetti S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol. 2010, 20:945-951.
108. Lundgren P., Strömberg J., Bäckström T., Wang M. Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3beta-hydroxy-5alpha-pregnan-20-one (isoallopregnanolone). Brain Res. 2003, 982:45-53.
109. Maitra R., Reynolds J.N. Modulation of GABAA receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABAA receptor isoforms. Can. J. Physiol. Pharmacol. 1998, 76:909-920.
110. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
111. Majewska M.D., Mienville J.M., Vicini S. Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neurosci. Lett. 1988, 90:279-284.
112. Maksay G., Fodor L. Differential effects of two major neurosteroids on cerebellar and cortical GABA(A) receptor binding and function. Eur. J. Pharmacol. 2011, 650:94-101.
113. Malayev A., Gibbs T.T., Farb D.H. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 2002, 135:901-909.
114. McArthur S., Gillies G.E. Peripheral vs. central sex steroid hormones in experimental parkinson's disease. Front. Endocrinol. (Lausanne) 2011, 2:82-87.
115. McDonald A.J., Mascagni F. Immunohistochemical localization of the beta 2 and beta 3 subunits of the GABAA receptor in the basolateral amygdala of the rat and monkey. Neuroscience 1996, 75:407-419.
116. Melcangi R.C., Garcia-Segura L.M., Mensah-Nyagan A.G. Neuroactive steroids: state of the art and new perspectives. Cell. Mol. Life Sci. 2008, 65:777-797.
117. Melcangi R.C., Caruso D., Levandis G., Abbiati F., Armentero M.T., Blandini F. Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease. J. Mol. Neurosci. 2012, 46:177-183.
118. Mellon S.H. Neurosteroid regulation of central nervous system development. Pharmacol. Ther. 2007, 116:107-124.
119. Mellon S.H., Griffin L.D., Compagnone N.A. Biosynthesis and action of neurosteroids. Brain Res. Brain Res. Rev. 2001, 37:3-12.
120. Mensah-Nyagan A.G., Do-Rego J.L., Beaujean D., Luu-The V., Pelletier G., Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev. 1999, 51:63-81.
121. Miller I.N., Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov. Disord. 2010, 25:2695-2703.
122. Morissette M., Di Paolo T. Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys. J. Neurosci. Res. 2009, 87:1634-1644.
123. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 2007, 52:1509-1520.
124. Morissette M., Al Sweidi S., Callier S., Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol. Cell. Endocrinol. 2008, 290:60-69.
125. Morita K., Her S. Progesterone pretreatment enhances serotonin-stimulated BDNF gene expression in rat c6 glioma cells through production of 5alpha-reduced neurosteroids. J. Mol. Neurosci. 2008, 34:193-200.
126. Motzo C., Porceddu M.L., Maira G., Flore G., Concas A., Dazzi L., Biggio G. Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosteroid allopregnanolone. J. Psychopharmacol. 1996, 10:266-272.
127. Naert G., Maurice T., Tapia-Arancibia L., Givalois L. Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 2007, 2:1062-1078.
128. Nielsen K.M., Soghomonian J.J. Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa. Neuroscience 2004, 123:31-42.
129. Nin, M.S., Martinez, L.A., Pibiri, F., Nelson, M., Pinna, G., 2011. Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression. Front. Endocrinol. (Lausanne), 2:73.
130. Nuwayhid S.J., Werling L.L. Steroids modulate N-methyl-d-aspartate-stimulated [3H] dopamine release from rat striatum via sigma receptors. J. Pharmacol. Exp. Ther. 2003, 306:934-940.
131. Obeso J.A., Lanciego J.L. Past, present, and future of the pathophysiological model of the Basal Ganglia. Front. Neuroanat. 2011, 5:39.
132. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temiño B., Mena-Segovia J., Rodríguez M., Olanow C.W. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol. 2008, 64(Suppl 2):S30-S46.
133. Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J., Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000, 100:53-62.
134. Olson W.L., Gruenthal M., Mueller M.E., Olson W.H. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am. J. Med. 1997, 102:60-66.
135. Ondo W.G., Silay Y.S. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial. Mov. Disord. 2006, 21:1614-1617.
136. Pan H.S., Penney J.B., Young A.B. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem. 1985, 45:1396-1404.
137. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
138. Park-Chung M., Malayev A., Purdy R.H., Gibbs T.T., Farb D.H. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res. 1999, 830:72-87.
139. Partridge L.D., Valenzuela C.F. Neurosteroid-induced enhancement of glutamate transmission in rat hippocampal slices. Neurosci. Lett. 2001, 301:103-106.
140. Petitclerc M., Bédard P.J., Di Paolo T. Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:491-497.
141. Pinna G. In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav. Pharmacol. 2010, 21:438-450.
142. Pinna G., Agis-Balboa R.C., Pibiri F., Nelson M., Guidotti A., Costa E. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem. Res. 2008, 33:1990-2007.
143. Raju P.M., Walker R.W., Lee M.A. Dyskinesia induced by gabapentin in idiopathic Parkinson's disease. Mov. Disord. 2007, 22:288-289.
144. Ramirez A.D., Liu X., Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003, 77:223-231.
145. Rangel-Barajas C., Silva I., Garcia-Ramirez M., Sanchez-Lemus E., Floran L., Aceves J., Erlij D., Floran B. 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 2008, 55:704-771.
146. Rangel-Barajas C., Silva I., Lopéz-Santiago L.M., Aceves J., Erlij D., Florán B. l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol. Dis. 2011, 41:51-61.
147. Robertson R.G., Clarke C.A., Boyce S., Sambrook M.A., Crossman A.R. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Brain Res. 1990, 531:95-104.
148. Robertson R.G., Graham W.C., Sambrook M.A., Crossman A.R. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res. 1991, 563:278-280.
149. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Lanciego J.L., Labandeira-Garcia J.L. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp. Neurol. 2010, 224:517-526.
150. Rojo A., Aguilar M., Garolera M.T., Cubo E., Navas I., Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat. Disord. 2003, 10:23-38.
151. Romeo E., Ströhle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 1998, 155:910-913.
152. Rougé-Pont F., Mayo W., Marinelli M., Gingras M., Le Moal M., Piazza P.V. The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur. J. Neurosci. 2002, 16:169-173.
153. Rupprecht R., Reul J.M., Trapp T., van Steensel B., Wetzel C., Damm K., Zieglgänsberger W., Holsboer F. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993, 11:523-530.
154. Rupprecht R., di Michele F., Hermann B., Ströhle A., Lancel M., Romeo E., Holsboer F. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Brain Res. Rev. 2001, 37:59-67.
155. Russell D.W., Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994, 63:25-61.
156. Sadri-Vakili G., Janis G.C., Pierce R.C., Gibbs T.T., Farb D.H. Nanomolar concentrations of pregnenolone sulfate enhance striatal dopamine overflow in vivo. J. Pharmacol. Exp. Ther. 2008, 327:840-845.
157. Schroeder J.A., Schneider J.S. GABA-opioid interactions in the globus pallidus: [D-Ala2]-Met-enkephalinamide attenuates potassium-evoked GABA release after nigrostriatal lesion. J. Neurochem. 2002, 82:666-673.
158. Schumacher M., Akwa Y., Guennoun R., Robert F., Labombarda F., Desarnaud F., Robel P., De Nicola A.F., Baulieu E.E. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J. Neurocytol. 2000, 29:307-326.
159. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., Akwa Y., Rajkowski K., Baulieu E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr. Rev. 2007, 28:387-439.
160. Schumacher M., Guennoun R., Stein D.G., De Nicola A.F. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol. Ther. 2007, 116:77-106.
161. Segovia J., Armstrong D.M., Benzing W.C., Hornby P.J. Striatal glutamic acid decarboxylase immunoreactivity is increased after dopaminergic deafferentation: densitometric analysis. Neurosci. Lett. 1991, 122:252-256.
162. Shen K.Z., Zhu Z.T., Munhall A., Johnson S.W. Synaptic plasticity in rat subthalamic nucleus induced by high-frequency stimulation. Synapse 2003, 50:314-319.
163. Shu H.J., Eisenman L.N., Jinadasa D., Covey D.F., Zorumski C.F., Mennerick S. Slow actions of neuroactive steroids at GABAA receptors. J. Neurosci. 2004, 24:6667-6675.
164. Shulman L.M., Bhat V. Gender disparities in Parkinson's disease. Expert Rev. Neurother. 2006, 6:407-416.
165. Sieghart W., Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2002, 2:795-816.
166. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998, 86:353-387.
167. Smith S.S., Gong Q.H., Li X., Moran M.H., Bitran D., Frye C.A., Hsu F.C. Withdrawal from 3alpha-OH-5alpha-pregnan-20-One using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor alpha4 subunit in association with increased anxiety. J. Neurosci. 1998, 18:5275-5284.
168. Soghomonian J.J., Laprade N. Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys. Synapse 1997, 27:122-132.
169. Stell B.M., Brickley S.G., Tang C.Y., Farrant M., Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc. Natl. Acad. Sci. USA 2003, 100:14439-14444.
170. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol. 2001, 145:669-679.
171. Strömberg J., Haage D., Taube M., Bäckström T., Lundgren P. Neurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor. Neuroscience 2006, 143:73-81.
172. Sun C., Ou X., Farley J.M., Stockmeier C., Bigler S., Brinton R.D., Wang J.M. Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:473-480.
173. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007, 30:228-235.
174. Tarazi F.I., Baldessarini R.J. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J. Neurosci. Res. 1999, 55:401-410.
175. Tenn C.C., Niles L.P. Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology 1997, 36:1659-1663.
176. Tenn C.C., Niles L.P. Sensitization of G protein-coupled benzodiazepine receptors in the striatum of 6-hydroxydopamine-lesioned rats. J. Neurochem. 1997, 69:1920-1926.
177. Tepper J.M., Abercrombie E.D., Bolam J.P. Basal ganglia macrocircuits. Prog. Brain Res. 2007, 160:3-7.
178. Thaker G.K., Nguyen J.A., Strauss M.E., Jacobson R., Kaup B.A., Tamminga C.A. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am. J. Psychiatry 1990, 147:445-451.
179. Tsutsui K., Ukena K., Takase M., Kohchi C., Lea R.W. Neurosteroid biosynthesis in vertebrate brains. Comp. Biochem. Physiol. C: Pharmacol. Toxicol. Endocrinol. 1999, 124:121-129.
180. Twelves D., Perkins K.S., Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 2003, 18:19-31.
181. Ueno S., Bracamontes J., Zorumski C., Weiss D.S., Steinbach J.H. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor. J. Neurosci. 1997, 17:625-634.
182. Ueno S., Tsutsui M., Toyohira Y., Minami K., Yanagihara N. Sites of positive allosteric modulation by neurosteroids on ionotropic gamma-aminobutyric acid receptor subunits. FEBS Lett. 2004, 566:213-217.
183. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA 1996, 93:12599-12604.
184. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA 1998, 95:3239-3244.
185. Vallée M., Mayo W., Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res. Brain Res. Rev. 2001, 37:301-312.
186. Van Blercom N., Lasa A., Verger K., Masramón X., Sastre V.M., Linazasoro G. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease. Clin. Neuropharmacol. 2004, 27:124-128.
187. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
188. van Wingen G.A., van Broekhoven F., Verkes R.J., Petersson K.M., Bäckström T., Buitelaar J.K., Fernández G. Progesterone selectively increases amygdala reactivity in women. Mol. Psychiatry 2008, 13:325-333.
189. VanLandingham J.W., Cutler S.M., Virmani S., Hoffman S.W., Covey D.F., Krishnan K., Hammes S.R., Jamnongjit M., Stein D.G. The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury. Neuropharmacology 2006, 51:1078-1085.
190. Videnovic, A., Golombek, D., 2012. Circadian and sleep disorders in Parkinson's disease. Exp. Neurol. pii: S0014-4886(12)00327-5. doi:. doi:10.1016/j.expneurol.2012.08.018.
191. Vila M., Herrero M.T., Levy R., Faucheux B., Ruberg M., Guillen J., Luquin M.R., Guridi J., Javoy-Agid F., Agid Y., Obeso J.A., Hirsch E.C. Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 1996, 46:802-809.
192. Vongher J.M., Frye C.A. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol. Biochem. Behav. 1999, 64:777-785.
193. Walker R.H., Moore C., Davies G., Dirling L.B., Koch R.J., Meshul C.K. Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat. PLoS One 2012, 7:e32919.
194. Wang M. Neurosteroids and GABA-A receptor function. Front. Endocrinol. (Lausanne) 2011, 2:44.
195. Wang H., Pickel V.M. Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus. J. Comp. Neurol. 2002, 442:392-404.
196. Wang J.M., Irwin R.W., Liu L., Chen S., Brinton R.D. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr. Alzheimer Res. 2007, 4:510-517.
197. Weiland N.G., Orchinik M. Specific subunit mRNAs of the GABAA receptor are regulated by progesterone in subfields of the hippocampus. Brain Res. Mol. Brain Res. 1995, 32:271-278.
198. West A.R., Grace A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 2002, 22:294-304.
199. West A.R., Floresco S.B., Charara A., Rosenkranz J.A., Grace A.A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann. N. Y. Acad. Sci. 2003, 1003:53-74.
200. Whittaker M.T., Gibbs T.T., Farb D.H. Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum. J. Neurochem. 2008, 107:510-521.
201. Wisden W., Herb A., Wieland H., Keinänen K., Lüddens H., Seeburg P.H. Cloning, pharmacological characteristics and expression pattern of the rat GABAA receptor alpha 4 subunit. FEBS Lett. 1991, 289(2):227-230.
202. Wojtal K., Trojnar M.K., Czuczwar S.J. Endogenous neuroprotective factors: neurosteroids. Pharmacol. Rep. 2006, 58:335-340.
203. Wonodi I., Adami H., Sherr J., Avila M., Hong L.E., Thaker G.K. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J. Clin. Psychopharmacol. 2004, 24:441-445.
204. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 2004, 75:637-639.
205. Yadav R., Shukla G., Goyal V., Singh S., Behari M. A case control study of women with Parkinson's disease and their fertility characteristics. J. Neurol. Sci. 2012, 319:135-138.
206. Yaghoubi N., Malayev A., Russek S.J., Gibbs T.T., Farb D.H. Neurosteroid modulation of recombinant ionotropic glutamate receptors. Brain Res. 1998, 801:153-160.
207. Yamaguchi T., Sheen W., Morales M. Glutamatergic neurons are present in the rat ventral tegmental area. Eur. J. Neurosci. 2007, 25:106-118.
208. Yamamoto N., Pierce R.C., Soghomonian J.J. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata. Brain Res. 2006, 1123:196-200.
209. Yu L., Liao P.C. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J. Neural Transm. 2000, 107:1139-1147.
210. Yu R., Ticku M.K. Chronic neurosteroid treatment produces functional heterologous uncoupling at the gamma-aminobutyric acid type A/benzodiazepine receptor complex in mammalian cortical neurons. Mol. Pharmacol. 1995, 47:603-610.
211. Zeng B.Y., Jolkkonen J., Jenner P., Marsden C.D. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 1995, 66:19-28.
212. Zhang L.L., Chen L., Xue Y., Yung W.H. Modulation of synaptic GABAA receptor function by zolpidem in substantia nigra pars reticulata. Acta Pharmacol. Sin. 2008, 29:161-168.
213. Zhu W.J., Vicini S. Neurosteroid prolongs GABAA channel deactivation by altering kinetics of desensitized states. J. Neurosci. 1997, 17:4022-4031.